Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia
Overview
- Phase
- Phase 2
- Intervention
- CPL500036 - low dose
- Conditions
- Schizophrenia
- Sponsor
- Celon Pharma SA
- Enrollment
- 189
- Locations
- 16
- Primary Endpoint
- Change from baseline in PANSS positive subscale at Day 28.
- Status
- Completed
- Last Updated
- 7 months ago
Overview
Brief Summary
The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..
Detailed Description
This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A \[PDE10A\] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient has a primary diagnosis of schizophrenia confirmed by clinical interview \[SCID-5-CT\].
- •Male or female patient aged 18 to 65, inclusive, at Screening.
- •The patient's with exacerbation of psychotic symptoms
- •The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
- •The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
- •The patient of childbearing potential willing to use acceptable forms of contraception.
- •The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
- •The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
- •The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.
Exclusion Criteria
- •The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
- •Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
- •The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
- •The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
- •The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
- •The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
- •The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
- •The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
- •The patient has chronic movement disorder that may interfere with the interpretation of study results.
- •The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
Arms & Interventions
CPL500036 low dose
Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.
Intervention: CPL500036 - low dose
CPL500036 high dose
Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.
Intervention: CPL500036 - high dose
Placebo
Patients are to receive placebo administered once dail for 28-days treatment period.
Intervention: Placebo
Outcomes
Primary Outcomes
Change from baseline in PANSS positive subscale at Day 28.
Time Frame: Day -1, Day 28
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.
Secondary Outcomes
- Change from Baseline in PANSS Subscales Using the Marder 5 factor Model at Weeks 1, 2, 3, and 4(Day -1, Week 1, 2, 3 and 4)
- Change from Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4(Day -1, Week 1, 2, 3 and 4)
- Number of abnormal clinically significant values in vital signs (heart rate, blood pressure, respiratory rate) results.(up to 6 weeks)
- Change from baseline in PANSS Total Score at Weeks 1, 2, 3, 4(Day -1, Week 1, 2, 3 and 4)
- Percentage of Clinical Responders Based on the PANSS Total Score.(Day -1, Week 1, 2, 3 and 4)
- Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.(Day -1, Week 1, 2, 3 and 4)
- CPL500036 AUC (0-24h) - Area under the curve from time zero to 24 hours(up to 24 hours after administration on Day 7)
- Change from Baseline in PANSS general psychopathology Subscale at Weeks 1, 2, 3 and 4(Day -1, Week 1, 2, 3 and 4)
- Number of abnormal clinically significant findings in electrocardiogram results.(up to 6 weeks)
- Number of adverse events.(up to 6 weeks)
- CPL500036 Tmax - Time corresponding to occurrence of Cmax(up to 24 hours after administration on Day 7)
- Change from baseline in PANSS positive subscale at Week 1, 2 and 3(Day -1, Week 1, 2 and 3)
- Change from Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) Score at Weeks 2 and 4.(Day -1, Week 2 and 4)
- Number of abnormal clinically significant values in laboratory tests (hematologic, clinical chemistry, coagulation and urinalysis) results.(up to 6 weeks)
- Change from Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4(Day -1, Week 1, 2, 3 and 4)
- CPL500036 Cmax - Maximum observed concentration(up to 24 hours after administration on Day 7)
- CPL500036 AUC T1/2 - Apparent terminal elimination half-life(up to 24 hours after administration on Day 7)
- Number of abnormal physical, neurological, ophthalmological and dermatological examination findings.(up to 6 weeks)
- CPL500036 Cthrough - Concentration immediately prior to dosing(up to 24 hours after administration on Day 7)
- Number and intensity of extrapyramidal side effects.(up to 6 weeks)
- CPL500036 CL/F (Apparent clearance) and Vz/F (apparent volume of distribution during terminal phase)(up to 24 hours after administration on Day 7)